Benzodiazepine treatment of catatonia

References

• 1 Fink M, Taylor MA. Catatonia. A Clinician's Guide To Diagnosis And Treatment. Cambridge University Press, Cambridge, UK (2003).
  Google Scholar
• 2 Fink M. Catatonia: a syndrome appears, disappears, and is rediscovered. Can. J. Psychiatry 54(7), 437–445 (2009).
  MedlineGoogle Scholar
• 3 Kolli V, Sharma A, Amani M, Bestha D, Chaturvedi R. ‘Meow meow’ (mephedrone) and catatonia. Innov. Clin. Neurosci. 10(2), 11–12 (2013).
  Google Scholar
• 4 Francis A, Fink M, Appiani F et al. Catatonia in diagnostic and statistical manual of mental disorders, fifth edition. J. ECT 26(4), 246–247 (2010).
  MedlineGoogle Scholar
• 5 Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr. Bull. 36(2), 239–242 (2010).
  MedlineGoogle Scholar
• 6 Rosebush PI, Mazurek MF. Pharmacotherapy of catatonia. In: Catatonia: From Psychopathology to Neurobiology. Caroff SN, Mann SC, Francis A, Fricchione GL (Eds). American Psychiatric Publishing Inc., Washington, DC 141–150 (2004).
  Google Scholar
• 7 Carroll BT, Kirkhart R, Ahuja N et al. Katatonia: a new conceptual understanding of catatonia and a new rating scale. Psychiatry (Edgmont.) 5(12), 42–50 (2008).
  MedlineGoogle Scholar
• 8 Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr. Scand. 93(2), 137–143 (1996).
  Medline CASGoogle Scholar
• 9 Fink M. Catatonia: syndrome or schizophrenia subtype? Recognition and treatment. J. Neural. Transm. 108(6), 637–644 (2001).
  Medline CASGoogle Scholar
• 10 Fink M, Taylor MA. The catatonia syndrome: forgotten but not gone. Arch. Gen. Psychiatry 66(11), 1173–1177 (2009).
  MedlineGoogle Scholar
• 11 Slooter AJ, Braun KP, Balk FJ, Van Nieuwenhuizen O, Van Der Hoeven J. Electroconvulsive therapy for malignant catatonia in childhood. Pediatr. Neurol. 32(3), 190–192 (2005).
  MedlineGoogle Scholar
• 12 Espinola-Nadurille M, Ramirez-Bermudez J, Fricchione GL. Pregnancy and malignant catatonia. Gen. Hosp. Psychiatry 29(1), 69–71 (2007).
  MedlineGoogle Scholar
• 13 Kelly KG, Zisselman M. Update on electroconvulsive therapy (ECT) in older adults. J. Am. Geriatr. Soc. 48(5), 560–566 (2000).
  Medline CASGoogle Scholar
• 14 Hudcova J, Schumann R. Electroconvulsive therapy complicated by life-threatening hyperkalemia in a catatonic patient. Gen. Hosp. Psychiatry 28(5), 440–442 (2006).
  MedlineGoogle Scholar
• 15 Grenier E, Ryan M, Ko E, Fajardo K, John V. Risperidone and Lorazepam concomitant use in clonazepam refractory catatonia: a case report. J. Nerv. Ment. Dis. 199(12), 987–988 (2011).
  MedlineGoogle Scholar
• 16 Benazzi F. Parenteral clonazepam for catatonia. Can. J. Psychiatry 36(4), 312 (1991).
  Medline CASGoogle Scholar
• 17 Kumar R. Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam. Aust. NZ J. Psychiatry 35(3), 391 (2001).
  Medline CASGoogle Scholar
• 18 Dutt A, Grover S, Chakrabarti S, Avasthi A, Kumar S. Phenomenology and treatment of Catatonia: a descriptive study from north India. Indian J. Psychiatry 53(1), 36–40 (2011).
  MedlineGoogle Scholar
• 19 Tsai MC, Huang TL. Lorazepam and diazepam for relieving catatonic features precipitated by initial hemodialysis in a uremic patient: a case report. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(2), 423–424 (2010).
  MedlineGoogle Scholar
• 20 Iseki K, Ikeda A, Kihara T et al. Impairment of the cortical GABAergic inhibitory system in catatonic stupor: a case report with neuroimaging. Epileptic Disord. 11(2), 126–131 (2009).
  MedlineGoogle Scholar
• 21 Wang HY, Huang TL. Benzodiazepines in catatonia associated with systemic lupus erythematosus. Psychiatry Clin. Neurosci. 60(6), 768–770 (2006).
  MedlineGoogle Scholar
• 22 Ungvari GS, Leung CM, Wong MK, Lau J. Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatr. Scand. 89(4), 285–288 (1994).
  Medline CASGoogle Scholar
• 23 Mcevoy JP, Lohr JB. Diazepam for catatonia. Am. J. Psychiatry 141(2), 284–285 (1984).
  Medline CASGoogle Scholar
• 24 Appleton R, Martland T, Phillips B. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst. Rev. (4), CD001905 (2002).
  MedlineGoogle Scholar
• 25 Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr. Neurol. 34(5), 355–359 (2006).
  MedlineGoogle Scholar
• 26 Peglow S, Prem V, Mcdaniel W. Treatment of catatonia with zolpidem. J. Neuropsychiatry Clin. Neurosci. 25(3), E13 (2013).
  MedlineGoogle Scholar
• 27 Northoff G, Steinke R, Czcervenka C et al. Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. J. Neurol. Neurosurg. Psychiatry 67(4), 445–450 (1999).
  Medline CASGoogle Scholar
• 28 Northoff G, Kotter R, Baumgart F et al. Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation. Schizophr. Bull. 30(2), 405–427 (2004).
  MedlineGoogle Scholar
• 29 Richter A, Grimm S, Northoff G. Lorazepam modulates orbitofrontal signal changes during emotional processing in catatonia. Hum. Psychopharmacol. 25(1), 55–62 (2010).
  Medline CASGoogle Scholar
• 30 Utumi Y, Iseki E, Arai H. Three patients with mood disorders showing catatonia and frontotemporal lobes atrophy. Psychogeriatrics 13(4), 254–259 (2013).
  MedlineGoogle Scholar
• 31 Tsujino N, Nemoto T, Yamaguchi T et al. Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment. Psychiatry Clin. Neurosci. 65(6), 600–603 (2011).
  Medline CASGoogle Scholar
• 32 Carroll BT, Thomas C, Tugrul KC, Coconcea C, Goforth HW. GABA(A) versus GABA(B) in catatonia. J. Neuropsychiatry Clin. Neurosci. 19(4), 484 (2007).
  MedlineGoogle Scholar
• 33 Starkstein SE, Petracca G, Teson A et al. Catatonia in depression: prevalence, clinical correlates, and validation of a scale. J. Neurol. Neurosurg. Psychiatry 60(3), 326–332 (1996).
  Medline CASGoogle Scholar
• 34 Fink M. Rediscovering catatonia: the biography of a treatable syndrome. Acta Psyhiatr. Scand. Suppl. (441), 1–47 (2013).
  Google Scholar
• 35 Northoff G. What catatonia can tell us about ‘top-down modulation’: a neuropsychiatric hypothesis. Behav. Brain Sci. 25(5), 555–577; discussion 578–604 (2002).
  MedlineGoogle Scholar
• 36 Carroll BT. The universal field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectr. 5(7), 26–33 (2000).
  Medline CASGoogle Scholar
• 37 Carroll BT, Goforth HW, Thomas C et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J. Neuropsychiatry Clin. Neurosci. 19(4), 406–412 (2007).
  Medline CASGoogle Scholar
• 38 Carroll B, Thomas C, Jayanti K, Hawkins JM, Burbage C. Treating persistent catatonia when benzodiazepines fail. Curr. Psychiatry 4(3), 56–64 (2005).
  Google Scholar
• 39 Thomas C, Carroll BT, Maley RT, Jayanti K, Koduri A. Memantine and catatonic schizophrenia. Am. J. Psychiatry 162(3), 626 (2005).
  MedlineGoogle Scholar
• 40 Gottmann K, Mittmann T, Lessmann V. BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. Exp. Brain Res. 199(3–4), 203–234 (2009).
  Medline CASGoogle Scholar
• 41 Huang TL, Lee CT. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J. Psychiatr. Res. 40(7), 664–668 (2006).
  MedlineGoogle Scholar
• 42 Thoenen H. Neurotrophins and neuronal plasticity. Science 270(5236), 593–598 (1995).
  Medline CASGoogle Scholar
• 43 Huang TL, Hung YY. Lorazepam reduces the serum brain-derived neurotrophic factor level in schizophrenia patients with catatonia. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(1), 158–159 (2009).
  Medline CASGoogle Scholar
• 44 Huopaniemi L, Keist R, Randolph A, Certa U, Rudolph U. Diazepam-induced adaptive plasticity revealed by alpha1 GABAA receptor-specific expression profiling. J. Neurochem. 88(5), 1059–1067 (2004).
  Medline CASGoogle Scholar
• 45 Marmigere F, Givalois L, Rage F, Arancibia S, Tapia-Arancibia L. Rapid induction of BDNF expression in the hippocampus during immobilization stress challenge in adult rats. Hippocampus 13(5), 646–655 (2003).
  Medline CASGoogle Scholar
• 46 Matsumoto T, Numakawa T, Yokomaku D et al. Brain-derived neurotrophic factor-induced potentiation of glutamate and GABA release: different dependency on signaling pathways and neuronal activity. Mol. Cell. Neurosci. 31(1), 70–84 (2006).
  Medline CASGoogle Scholar
• 47 Roberts DS, Hu Y, Lund IV, Brooks-Kayal AR, Russek SJ. Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons. J. Biol. Chem. 281(40), 29431–29435 (2006).
  Medline CASGoogle Scholar
• 48 Hoirisch-Clapauch S, Mezzasalma MA, Nardi AE. Pivotal role of tissue plasminogen activator in the mechanism of action of electroconvulsive therapy. J. Psychopharmacol. 28(2), 99–105 (2013).
  MedlineGoogle Scholar
• 49 Huang TL, Ree SC, Huang YC, Liu HY, Yang YY. Catatonic features: differential diagnosis and treatments at an emergency unit. Psychiatry Clin. Neurosci. 53(1), 63–66 (1999).
  Medline CASGoogle Scholar
• 50 Huang TL. Lorazepam and diazepam rapidly relieve catatonic signs in patients with schizophrenia. Psychiatry Clin. Neurosci. 59(1), 52–55 (2005).
  Medline CASGoogle Scholar
• 51 Lin CC, Huang TL. Lorazepam-diazepam protocol for catatonia in schizophrenia: a 21-case analysis. Compr. Psychiatry 54(8), 1210–1214 (2013).
  MedlineGoogle Scholar
• 52 Hung YY, Huang TL. Lorazepam and diazepam rapidly relieve catatonic features in major depression. Clin. Neuropharmacol. 29(3), 144–147 (2006).
  Medline CASGoogle Scholar
• 53 Huang YC, Lin CC, Hung YY, Huang TL. Rapid relief of catatonia in mood disorder by lorazepam and diazepam. Biomed. J. 36(1), 35–39 (2013).
  MedlineGoogle Scholar
• 54 Hung YY, Huang TL. Lorazepam and diazepam for relieving catatonic features in multiple sclerosis. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(7), 1537–1538 (2007).
  Medline CASGoogle Scholar
• 55 Huang CE, Huang TL. Intramuscular lorazepam in catatonia in patients with acute renal failure: a report of two cases. Chang. Gung. Med. J. 33(1), 106–109 (2010).
  MedlineGoogle Scholar
• 56 Tsai MC, Huang TL. Severe neuroleptic malignant syndrome: successful treatment with high-dose lorazepam and diazepam: a case report. Chang. Gung. Med. J. 33(5), 576–580 (2010).
  MedlineGoogle Scholar
• 57 Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann. Neurol. 58(4), 594–604 (2005).
  MedlineGoogle Scholar
• 58 Dalmau J, Tuzun E, Wu HY et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 61(1), 25–36 (2007).
  Medline CASGoogle Scholar
• 59 Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 10(1), 63–74 (2011).
  Medline CASGoogle Scholar
• 60 Jones KC, Benseler SM, Moharir M. Anti-NMDA receptor encephalitis. Neuroimaging Clin. N. Am. 23(2), 309–320 (2013).
  MedlineGoogle Scholar
• 61 Dalmau J, Gleichman AJ, Hughes EG et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 7(12), 1091–1098 (2008).
  Medline CASGoogle Scholar
• 62 Kaestner F, Mostert C, Behnken A et al. Therapeutic strategies for catatonia in paraneoplastic encephalitis. World J. Biol. Psychiatry 9(3), 236–240 (2008).
  MedlineGoogle Scholar
• 63 Lee A, Glick DB, Dinwiddie SH. Electroconvulsive therapy in a pediatric patient with malignant catatonia and paraneoplastic limbic encephalitis. J. ECT 22(4), 267–270 (2006).
  MedlineGoogle Scholar
• 64 Braakman HM, Moers-Hornikx VM, Arts BM, Hupperts RM, Nicolai J. Pearls & Oysters: electroconvulsive therapy in anti-NMDA receptor encephalitis. Neurology 75(10), e44–e46 (2010).
  Medline CASGoogle Scholar
• 65 Creten C, Van Der Zwaan S, Blankespoor RJ et al. Late onset autism and anti-NMDA-receptor encephalitis. Lancet 378(9785), 98 (2011).
  MedlineGoogle Scholar
• 66 Wilson JE, Shuster J, Fuchs C. Anti-NMDA receptor encephalitis in a 14-year-old female presenting as malignant catatonia: medical and psychiatric approach to treatment. Psychosomatics 54(6), 585–589 (2013).
  MedlineGoogle Scholar
• 67 Bozkurt H, Mukaddes NM. Catatonia in a child with autistic disorder. Turk. J. Pediatr. 52(4), 435–438 (2010).
  MedlineGoogle Scholar
• 68 De Winter CF, Van Dijk F, Verhoeven WM, Dhossche DM, Stolker JJ. Autism and catatonia: successful treatment using lorazepam. A case study. Tijdschr. Psychiatr. 49(4), 257–261 (2007).
  Medline CASGoogle Scholar
• 69 Dhossche DM, Wachtel LE. Catatonia is hidden in plain sight among different pediatric disorders: a review article. Pediatr. Neurol. 43(5), 307–315 (2010).
  MedlineGoogle Scholar
• 70 Narayanaswamy JC, Tibrewal P, Zutshi A, Srinivasaraju R, Math SB. Clinical predictors of response to treatment in catatonia. Gen. Hosp. Psychiatry 34(3), 312–316 (2012).
  MedlineGoogle Scholar